Northwest Biotherapeutics (NWBO) Total Non-Current Liabilities (2010 - 2026)

Northwest Biotherapeutics' Total Non-Current Liabilities history runs 17 years deep, the most recent figure standing at $35.1 million for Q1 2026.

• In Q1 2026, Total Non-Current Liabilities rose 19.99% year-over-year to $35.1 million; the TTM figure through Mar 2026 stood at $35.1 million (up 19.99% YoY), while the FY2025 annual figure was $37.2 million, down 0.73% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $35.1 million, down from $37.2 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $38.0 million in Q3 2025, with the low at $10.1 million in Q3 2022.
• The 5-year median for Total Non-Current Liabilities is $29.3 million (2025), against an average of $26.4 million.
• The sharpest annual moves came in 2022 and 2023: Total Non-Current Liabilities tumbled 65.9% in 2022, then soared 186.81% in 2023.
• Northwest Biotherapeutics' Total Non-Current Liabilities stood at $10.4 million in 2022, then jumped by 186.81% to $29.7 million in 2023, then increased by 25.97% to $37.4 million in 2024, then dropped by 0.73% to $37.2 million in 2025, then decreased by 5.44% to $35.1 million in 2026.
• Business Quant data shows NWBO's Total Non-Current Liabilities at $35.1 million in Q1 2026, $37.2 million in Q4 2025, and $38.0 million in Q3 2025.